Enliven Therapeutics (NASDAQ:ELVN) Issues Earnings Results, Beats Expectations By $0.07 EPS

Enliven Therapeutics (NASDAQ:ELVN) released its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07, Zacks reports. The business had revenue of $0.03 million during the quarter.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $20.74 on Friday. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -10.92 and a beta of 1.04. Enliven Therapeutics has a 12 month low of $10.90 and a 12 month high of $30.03. The firm’s 50 day simple moving average is $21.59 and its 200-day simple moving average is $23.80.

Insider Activity

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $265,330. The trade was a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,784 shares of company stock worth $1,092,375 in the last quarter. Corporate insiders own 29.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ELVN. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.